anti-CD59 antibody

Arigo Biolaboratories

anti-CD59 antibody

23

Flow Cytometry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Polyclonal

0.5 mg/ml

Unconjugated

CD59

CD59 molecule (CD59 blood group)

16.3A5; 1F5; 1F5 antigen; 20 kDa homologous restriction factor; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 blood group antigen; CD59 glycoprotein; CD59 molecule, complement regulatory protein; EJ16; EJ30; EL32; G344; HRF20; HRF-20; human leukocyte antigen MIC11; Ly-6-like protein; lymphocytic antigen CD59/MEM43; MACIF; MAC-IP; MEM43; MEM43 antigen; membrane attack complex (MAC) inhibition factor; membrane attack complex inhibition factor; membrane inhibitor of reactive lysis; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20; protectin; surface anitgen recognized by monoclonal antibody 16.3A5; T cell-activating protein

Rabbit

IgG

This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008]

Human

-20°C

12352203